Ballicules.com

Lofexidine

LUCEMYRA

What it isCentral alpha-2 agonist; opioid withdrawal symptoms.

Why this oneIt is the only non-opioid agent approved for withdrawal, so it can be used where buprenorphine cannot.

What limits itHypotension, bradycardia and QT prolongation. It treats symptoms only and does nothing for craving or relapse.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Mitigation of opioid withdrawal symptomsAdults0.54 mg (three 0.18 mg tablets) QID, 5–6 hr apartguided by symptoms0.72 mg/dose; 2.88 mg/day; up to 14 days

Renal eGFR 30–89.9: 0.36 mg (2 tabs) QID; <30 / ESRD / dialysis: 0.18 mg (1 tab) QID

Hepatic Mild: 0.54 mg (3 tabs) QID; moderate: 0.36 mg (2 tabs) QID; severe: 0.18 mg (1 tab) QID

Single dose ≤0.72 mg; total ≤2.88 mg/day; treat up to 14 days

Instructions

Cautions

Adverse reactions

Pregnancy Safety not established; animal harm (resorptions, litter loss, stillbirths) at exposures below human

Lactation No human data; exercise caution in nursing women

NO BOXED WARNINGS

Principal riskHypotension and QT prolongation; it does nothing for craving

Cost, est. cash$300–$2,500/month

Generic entry2032 est.

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades2 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Lofexidine ballicule

Lofexidine ballicule: receptor binding, kinetics and half-life diagram

Open Lofexidine in the interactive console ↗

Memory aids: mascots and interaction avatars

Lofexidine LUCEMYRA mascot mnemonic cartoon
“Lose my Loaf”
orange plus signs → alpha-2 agonist

Open Lofexidine in the interactive console ↗